Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.
体外研究(In Vitro)
Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin.Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Male Wistar rats weighing 200-250 g, ball
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.[2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res. 2001 Feb 1;101(3):127-38.